These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30630705)

  • 41. In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.
    Chiu PW; Lui SSY; Hung KSY; Chan RCK; Chan Q; Sham PC; Cheung EFC; Mak HKF
    Schizophr Res; 2018 Mar; 193():295-303. PubMed ID: 28751130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Exploratory Study of Spectroscopic Glutamatergic Correlates of Cortical Excitability in Depressed Adolescents.
    Lewis CP; Port JD; Frye MA; Vande Voort JL; Ameis SH; Husain MM; Daskalakis ZJ; Croarkin PE
    Front Neural Circuits; 2016; 10():98. PubMed ID: 27965544
    [No Abstract]   [Full Text] [Related]  

  • 43. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.
    Théberge J; Al-Semaan Y; Williamson PC; Menon RS; Neufeld RW; Rajakumar N; Schaefer B; Densmore M; Drost DJ
    Am J Psychiatry; 2003 Dec; 160(12):2231-3. PubMed ID: 14638596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glutathione and glutamate in schizophrenia: a 7T MRS study.
    Kumar J; Liddle EB; Fernandes CC; Palaniyappan L; Hall EL; Robson SE; Simmonite M; Fiesal J; Katshu MZ; Qureshi A; Skelton M; Christodoulou NG; Brookes MJ; Morris PG; Liddle PF
    Mol Psychiatry; 2020 Apr; 25(4):873-882. PubMed ID: 29934548
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).
    Tayoshi S; Sumitani S; Taniguchi K; Shibuya-Tayoshi S; Numata S; Iga J; Nakataki M; Ueno S; Harada M; Ohmori T
    Schizophr Res; 2009 Mar; 108(1-3):69-77. PubMed ID: 19097753
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy.
    Tandon N; Bolo NR; Sanghavi K; Mathew IT; Francis AN; Stanley JA; Keshavan MS
    Schizophr Res; 2013 Aug; 148(1-3):59-66. PubMed ID: 23791389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.
    Smesny S; Langbein K; Rzanny R; Gussew A; Burmeister HP; Reichenbach JR; Sauer H
    Schizophr Res; 2012 Jul; 138(2-3):164-70. PubMed ID: 22516552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis.
    Bojesen KB; Ebdrup BH; Jessen K; Sigvard A; Tangmose K; Edden RAE; Larsson HBW; Rostrup E; Broberg BV; Glenthøj BY
    Psychol Med; 2020 Oct; 50(13):2182-2193. PubMed ID: 31524118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients.
    Birur B; Kraguljac NV; VerHoef L; Morgan CJ; Jindal RD; Reid MA; Luker A; Lahti AC
    Transl Psychiatry; 2020 Jan; 10(1):15. PubMed ID: 32066680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.
    Tarumi R; Tsugawa S; Noda Y; Plitman E; Honda S; Matsushita K; Chavez S; Sawada K; Wada M; Matsui M; Fujii S; Miyazaki T; Chakravarty MM; Uchida H; Remington G; Graff-Guerrero A; Mimura M; Nakajima S
    Neuropsychopharmacology; 2020 Mar; 45(4):632-640. PubMed ID: 31842203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study.
    Huang LC; Lin SH; Tseng HH; Chen KC; Abdullah M; Yang YK
    Psychol Med; 2023 May; 53(7):3220-3227. PubMed ID: 35197141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential neurometabolite alterations in brains of medication-free individuals with bipolar disorder and those with unipolar depression: a two-dimensional proton magnetic resonance spectroscopy study.
    Li H; Xu H; Zhang Y; Guan J; Zhang J; Xu C; Shen Z; Xiao B; Liang C; Chen K; Zhang J; Wu R
    Bipolar Disord; 2016 Nov; 18(7):583-590. PubMed ID: 27870506
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cannabidiol modulation of hippocampal glutamate in early psychosis.
    O'Neill A; Annibale L; Blest-Hopley G; Wilson R; Giampietro V; Bhattacharyya S
    J Psychopharmacol; 2021 Jul; 35(7):814-822. PubMed ID: 33860709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder.
    Ehrlich A; Schubert F; Pehrs C; Gallinat J
    Psychiatry Res; 2015 Aug; 233(2):73-80. PubMed ID: 26050195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of age and sex on the concentrations of glutamate and glutamine in the human brain.
    Hädel S; Wirth C; Rapp M; Gallinat J; Schubert F
    J Magn Reson Imaging; 2013 Dec; 38(6):1480-7. PubMed ID: 23564615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolite activity in the anterior cingulate cortex during a painful stimulus using functional MRS.
    Archibald J; MacMillan EL; Graf C; Kozlowski P; Laule C; Kramer JLK
    Sci Rep; 2020 Nov; 10(1):19218. PubMed ID: 33154474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients.
    van der Pluijm M; Alting M; Schrantee A; Edden RAE; Booij J; de Haan L; van de Giessen E
    Schizophr Res; 2024 Feb; 264():471-478. PubMed ID: 38277736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone.
    Kraguljac NV; White DM; Hadley JA; Visscher K; Knight D; ver Hoef L; Falola B; Lahti AC
    Neuroimage Clin; 2016; 10():146-58. PubMed ID: 26793436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis.
    Bojesen KB; Broberg BV; Fagerlund B; Jessen K; Thomas MB; Sigvard A; Tangmose K; Nielsen MØ; Andersen GS; Larsson HBW; Edden RAE; Rostrup E; Glenthøj BY
    Biol Psychiatry; 2021 Feb; 89(3):278-287. PubMed ID: 32928500
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels.
    Ochi R; Plitman E; Patel R; Tarumi R; Iwata Y; Tsugawa S; Kim J; Honda S; Noda Y; Uchida H; Devenyi GA; Mimura M; Graff-Guerrero A; Chakravarty MM; Nakajima S
    J Psychiatry Neurosci; 2022; 47(1):E1-E10. PubMed ID: 35027443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.